Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals
  4. Vaccines

COVID-19 Vaccines - Niger

Niger
  • In Niger, the revenue in the COVID-19 Vaccines market is estimated to reach US$38.84m in 2024.
  • This projection indicates a positive trend in the market's financial performance.
  • Furthermore, it is expected that the revenue will continue to grow at an annual rate of -16.47% from 2024 to 2029, resulting in a market volume of US$15.80m by 2029.
  • When considering the global context, it is noteworthy that United States is expected to generate the highest revenue in the COVID-19 Vaccines market.
  • In 2024, the projected revenue for the United States is US$4.39bn.
  • This highlights the significant market presence and potential of the United States in this industry.
  • Niger is experiencing a slow rollout of COVID-19 vaccines due to logistical challenges in its remote and underdeveloped regions.

Definition:
This market covers vaccines against COVID-19. Included are different types of vaccines (mRNA-based, viral vector vaccines).

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, Moderna, Biontech, Johnson & Johnson, AstraZeneca

In-Scope

  • COVID-19 vaccines
  • mRNA-based vaccines
  • Viral vector vaccines

Out-Of-Scope

  • Vaccines against other diseases
  • Antivirals
Pharmaceuticals: market data & analysis - Cover

Market Insights report

Pharmaceuticals: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The COVID-19 pandemic has affected every country in the world, including Niger. As the world races to develop and distribute vaccines to combat the virus, the COVID-19 vaccines market in Niger has seen some notable trends and developments.

    Customer preferences:
    Niger, like many other developing countries, has a low vaccination rate. The population is largely hesitant to receive vaccines due to mistrust and misinformation. Additionally, there is a preference for traditional medicine over Western medicine. This presents a challenge for the COVID-19 vaccines market in Niger as it tries to gain traction.

    Trends in the market:
    Despite the challenges, the COVID-19 vaccines market in Niger is slowly gaining momentum. The government has launched a vaccination campaign to encourage the population to get vaccinated. This campaign has led to an increase in demand for vaccines, which has been met with supply from various sources such as the COVAX facility.

    Local special circumstances:
    Niger is a landlocked country in West Africa with a population of over 24 million people. The country is one of the poorest in the world and faces a number of challenges such as food insecurity, poverty, and a lack of infrastructure. These challenges have made it difficult for the government to distribute vaccines to the population.

    Underlying macroeconomic factors:
    The COVID-19 pandemic has had a significant impact on the economy of Niger. The country has experienced a decline in economic activity due to the pandemic and the measures taken to contain it. The government has had to redirect resources to combat the pandemic, which has further strained the economy. However, the country has received support from international organizations such as the World Bank and the International Monetary Fund to help mitigate the economic impact of the pandemic.In conclusion, the COVID-19 vaccines market in Niger is slowly gaining momentum despite the challenges posed by low vaccination rates and a preference for traditional medicine. The government's vaccination campaign and the supply of vaccines from various sources have helped to increase demand for vaccines. However, the country's economic challenges and lack of infrastructure remain a hindrance to the distribution of vaccines to the population.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Pharmaceuticals: market data & analysis - BackgroundPharmaceuticals: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Coronavirus (COVID-19): vaccines and vaccination campaign

    As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.